Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Nurexone Biologic Inc V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of... see more

Current News (TSXV:NRX)

NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production

Newsfile 4 days ago

NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise

GlobeNewswire January 30, 2026

NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

GlobeNewswire December 19, 2025

NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways

GlobeNewswire December 12, 2025

NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 28, 2025

NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

GlobeNewswire November 12, 2025

NurExone Accepted into ARMI's BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing

GlobeNewswire November 3, 2025

NurExone Invited Presenter at Precision EV Forum in Cambridge, UK

GlobeNewswire October 21, 2025

NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

GlobeNewswire October 8, 2025
View More News ››

Opinion & Analysis (TSXV:NRX)

Developing new therapies for traumatic central nervous system injuries

Lyndsay Malchuk May 21, 2025

Exosome production crucial for regenerative therapy research and development

Lyndsay Malchuk February 20, 2025

A potential breakthrough in spinal cord and optic nerve injury treatment

Research December 19, 2024

NurExone Biologic announces important test results

Research December 11, 2024

Revolutionary biopharma company makes waves across the globe

Lyndsay Malchuk July 10, 2024

ExoTherapy offers hope for treating acute spinal cord injuries

Brieanna McCutcheon  September 19, 2023
View More Opinion ››

Bullboard Posts (TSXV:NRX)

Read the FRC analyst note on NurExone’s preclinical success

Disseminated on behalf of NurExone Biologic Inc. (TSXV: NRX / OTCQB: NRXBF / FSE: J90). Update: NurExone’s ExoPTEN showed strong...
Investorsnews - July 21, 2025

FRC analysts' Opinion on this develop

NurExone Biologic provided updates on research related to spinal cord injury treatment. Analysts have commented on the latest study...
cmarketinsights - March 18, 2025

Linkedin Post

CEO Lior Shaltiel, PhD on Linkedin: A huge hats off to NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) Scientific Advisory Board ...
Flintstone60 - January 31, 2025

FRC analysts' Opinion on this develop

 R&D Boost: Funding secured to accelerate development of ExoPTEN, a groundbreaking treatment for spinal cord injuries. What’s...
cmarketinsights - January 27, 2025

Exosome Based Therapies

NurExone chose to base its ultimate drug delivery platform on exosomes-nanosized extracellular vesicles-due to their natural ability to...
javaman12 - January 14, 2025

2025 Is The Critical Year For FDA Approval!

A near term 'Investigational New Drug' (IND) submission will be quickly followed by Phase I/IIa Human trials to help wheel chair...
javaman12 - January 14, 2025
View more Bullboard ››

Boron One Holdings Inc.

Boron One Holdings Inc.

Boron One Holdings Inc. engages in the acquisition, exploration, and development of mineral properties in Serbia. The company ...
View More »

Podcasts